Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Jul 27, 2010


Affymetrix has launched QuantiGene ViewRNA Assay formats to support in situ multiplex gene expression analysis.

According to Affy, its branched DNA-based QuantiGene ViewRNA Assays quantitate gene expression while localizing RNA trafficking within the cell at the single-copy level. The five-hour QuantiGene ViewRNA Assay is capable of multiplex gene expression in 96- or 384-well formats for high-throughput phenotypic and reporter gene compound screening.

Affy now also offers a single-plex tissue assay that the firm said can be considered an alternative to immunohistochemistry. Affy said its tissue assay can detect genes in formalin-fixed, paraffin-embedded or cryogenic tissue sections.

QuantiGene ViewRNA Assays can also be used in a number of other applications, including quantifying target mRNA following RNAi gene silencing; biomarker validation testing; stem cell characterization, differentiation, and quality control; viral host cell interactions; and validating microarray gene expression results, Affymetrix said.

Affymetrix this week also released a data set based on validation of SNPs from the 1000 Genomes Project. The firm said the data will give researchers access to more rare mutations for genome-wide association studies and will enable the design of custom arrays for a variety of applications, including the validation of sequencing results.

Affy has used its Axiom Genotyping Solution to screen millions of SNPs across multiple populations. The data set in the current release includes approximately 500,000 SNPs from the 1000 Genomes Project that have been genotyped across the 270 HapMap samples.

More information about the data set is available on the array vendor's website.

Randox Laboratories this week launched Evidence Evolution, the latest instrument in its Evidence family of immunoassay analyzers. The new system supports the analysis of Randox's menu of protein array assays.

Atlas Biolabs said last week that it has begun offering SNP genotyping services using Sequenom's MassArray Analyzer platform.

MassArray relies on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for SNP genotyping of single nucleotide polymorphisms. Berlin-based Atlas said the system can be used for validating potential biomarkers identified by next-generation sequencing, for fine mapping of genome-wide association study data, and for applications that employ defined SNP panels.

Atlas also offers whole-genome SNP genotyping on the Affymetrix and Illumina platforms.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.